Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease - PubMed (original) (raw)
Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease
Andreas Stallmach et al. Int J Colorectal Dis. 2004 Jul.
Abstract
Background and aims: Immunoregulatory properties of cytokines may contribute to pathological immune reactions in inflammatory bowel disease. There is an urgent need for a simple and dependable means for quantitating inflammatory activity in mucosal biopsies and assessing relapse risk particularly in patients with active Crohn's disease (CD).
Patients and methods: Cytokine and chemokine transcripts were quantified using real-time PCR in mucosal biopsy specimens from 70 patients with active inflammatory bowel disease (CD, n=45; ulcerative colitis n=25) and 16 patients with specific colitis (ischemic colitis, infectious colitis). Controls were 12 patients with noninflammatory conditions. CD patients with steroid-induced remission (n=20) were followed for up to 12 months.
Results: Compared to not-inflamed mucosa the vast majority of active CD tissue samples expressed significantly elevated transcript levels of IL-1beta, IL-8, IL-23, MRP-14, MIP2alpha, and MMP-1. Moreover, increased cytokine transcript levels were detected in both active ulcerative colitis and specific colitis. Importantly, TNF-alpha, IFN-gamma, CD40L, and IL-23 transcripts increased in active CD only. Transcript levels (MRP-14, IL-8, MMP-1, MIP2alpha) were correlated with clinical disease activity (CDAI) and endoscopic scoring indices. Medical treatment induced stable remission in 14 of 20 patients which was paralleled by a reduction in increased transcript levels. All six patients without normalization of MIP2alpha, MRP-14, TNF-alpha, and IL-1beta transcripts developed an early relapse (n=5) or chronic activity (n=1) during follow-up.
Conclusion: Elevated proinflammatory cytokine transcripts in active CD may underlie disease reactivation and chronicity. Real-time PCR quantification is a simple and objective method for grading inflammation of intestinal mucosa and may be useful in identifying patients who would benefit from anti-inflammatory remission maintenance.
Similar articles
- Predictive value of mucosal TNF-alpha transcripts in steroid-refractory Crohn's disease patients receiving intensive immunosuppressive therapy.
Schmidt C, Giese T, Hermann E, Zeuzem S, Meuer SC, Stallmach A. Schmidt C, et al. Inflamm Bowel Dis. 2007 Jan;13(1):65-70. doi: 10.1002/ibd.20012. Inflamm Bowel Dis. 2007. PMID: 17206641 - Cytokine/chemokine messenger-RNA expression profiles in ulcerative colitis and Crohn's disease.
Autschbach F, Giese T, Gassler N, Sido B, Heuschen G, Heuschen U, Zuna I, Schulz P, Weckauf H, Berger I, Otto HF, Meuer SC. Autschbach F, et al. Virchows Arch. 2002 Nov;441(5):500-13. doi: 10.1007/s00428-002-0684-z. Epub 2002 Jul 23. Virchows Arch. 2002. PMID: 12447682 - Normalization of mucosal cytokine gene expression levels predicts long-term remission after discontinuation of anti-TNF therapy in Crohn's disease.
Rismo R, Olsen T, Cui G, Paulssen EJ, Christiansen I, Johnsen K, Florholmen J, Goll R. Rismo R, et al. Scand J Gastroenterol. 2013 Mar;48(3):311-9. doi: 10.3109/00365521.2012.758773. Epub 2013 Jan 10. Scand J Gastroenterol. 2013. PMID: 23302000 Clinical Trial. - MIG in Crohn's disease.
Caruso C. Caruso C. Clin Ter. 2019 May-Jun;170(3):e206-e210. doi: 10.7417/CT.2019.2134. Clin Ter. 2019. PMID: 31173051 Review. - Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease?
Arnott ID, Watts D, Ghosh S. Arnott ID, et al. Aliment Pharmacol Ther. 2002 May;16(5):857-67. doi: 10.1046/j.1365-2036.2002.01242.x. Aliment Pharmacol Ther. 2002. PMID: 11966492 Review.
Cited by
- Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn's Disease.
Kwon Y, Kim ES, Kim YZ, Choe YH, Kim MJ. Kwon Y, et al. Biomedicines. 2022 Sep 23;10(10):2372. doi: 10.3390/biomedicines10102372. Biomedicines. 2022. PMID: 36289634 Free PMC article. - Could Mucosal TNF Transcript as a Biomarker Candidate Help Optimize Anti-TNF Biological Therapy in Patients With Ulcerative Colitis?
Cui G, Florholmen J, Goll R. Cui G, et al. Front Immunol. 2022 May 19;13:881112. doi: 10.3389/fimmu.2022.881112. eCollection 2022. Front Immunol. 2022. PMID: 35663996 Free PMC article. Review. - NSAID-Associated Small Intestinal Injury: An Overview From Animal Model Development to Pathogenesis, Treatment, and Prevention.
Zhang M, Xia F, Xia S, Zhou W, Zhang Y, Han X, Zhao K, Feng L, Dong R, Tian D, Yu Y, Liao J. Zhang M, et al. Front Pharmacol. 2022 Feb 9;13:818877. doi: 10.3389/fphar.2022.818877. eCollection 2022. Front Pharmacol. 2022. PMID: 35222032 Free PMC article. Review. - Mapping Transcriptome Data to Protein-Protein Interaction Networks of Inflammatory Bowel Diseases Reveals Disease-Specific Subnetworks.
Maden SF, Acuner SE. Maden SF, et al. Front Genet. 2021 Aug 18;12:688447. doi: 10.3389/fgene.2021.688447. eCollection 2021. Front Genet. 2021. PMID: 34484291 Free PMC article. - Effect of Anti-TNF Therapy on Mucosal Apoptosis Genes Expression in Crohn's Disease.
Lykowska-Szuber L, Walczak M, Skrzypczak-Zielinska M, Suszynska-Zajczyk J, Stawczyk-Eder K, Waszak K, Eder P, Wozniak A, Krela-Kazmierczak I, Slomski R, Dobrowolska A. Lykowska-Szuber L, et al. Front Immunol. 2021 Mar 9;12:615539. doi: 10.3389/fimmu.2021.615539. eCollection 2021. Front Immunol. 2021. PMID: 33767696 Free PMC article.
References
- Digestion. 1995;56(5):406-14 - PubMed
- Gastroenterology. 1990 Apr;98(4):811-8 - PubMed
- Gastroenterology. 1997 Jul;113(1):118-26 - PubMed
- Gastroenterology. 1999 Oct;117(4):814-22 - PubMed
- Clin Exp Immunol. 1995 Sep;101(3):428-35 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous